Launching of "MIROL Ophth. Soln. 0.5%", a Long-acting Eye Drop for Glaucoma and Ocular Hypertension(February 21, 2001)
Kyorin Pharmaceutical Co., Ltd. (president: Ikuo Ogihara; headquarters: Tokyo) launched on February 21, 2001 "MIROL Ophth. Soln. 0.5%", a long-acting eye drop for glaucoma and ocular hypertension through KAKEN PHARMACEUTICAL CO., LTD. (president: Shiro Inui; headquarters: Tokyo).

Developed by Allergan, Inc. of the US and licensed to Kyorin, MIROL Ophth. Soln. 0.5% shows excellent efficacy for glaucoma and ocular hypertension with once-daily administration. It is a non-selective β-blocking agent with α1-blocking activity which shows long-lasting intraocular pressure lowering effects. It has been widely used in many countries including the US and Europe since 1985, and its effectiveness and safety are highly appreciated.